ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ACET / news
IXHL (37) LITS (43) RMTI (23) RNAZ (35) ⌘ Pro Terminal →

Why ACET Stock dropped -6.43% Today — RQD Quant Desk Flash

$3.20 -6.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.16

Adicet Bio Inc. (ACET) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $30.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACET Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ACET stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Adicet Bio Inc. (NASDAQ: ACET) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.20 (-6.43% 1D, market cap $30.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ACET ranks #732 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ACET compare to IXHL and LITS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACET carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IXHL (Incannex Healthcare Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $29.9M) and LITS (Lite Strategy Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -18.9%, cap $29.4M). Among the 5-stock peer group, ACET leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACET?
▼

Per ACET's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001720580), Adicet Bio Inc. generated $341.9M in revenue (-4.3% YoY), -$116.8M in net income, and -$97.0M in free cash flow against $192.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.16 (-1.35%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (7)Whales (3)SEC (10)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.6% Base Target
$12 Bull$3 Base$2 Bear
📬 FREE ACET RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACET)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY ACET SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$4.89-8.2% Next Q
Q2 (-2Q)
37
Grade E$4.49-15.1% Next Q
Q3 (-1Q)
35
Grade E$3.81-16% Next Q
Current
32
Grade E$3.20-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACET Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACET currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.81) and Max Pain ($3.36) forces dealer call-delta covering toward $12.41.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACET• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ACET Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why ACET Stock dropped -6.43% Today — RQD Quant Desk Flash

Adicet Bio Inc. (ACET) dropped -6.43% to $3.20, trading at 2% of its 52-week range ($3.2 – $11.82). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($3.2 – $11.82) with RSI-14 at 20 (OVERSOLD (<32)).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.20 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ACET Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACET)

  • ✓Walkthrough of ACET's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ACET // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.40%▼ SUPPORT BREAKDOWN
2026-11-04O $3.42H $3.42L $3.20C $3.20VOL 250.3K
RES: $10.27SUP: $7.81SMA50: $6.81SMA200: $7.62
$10.44$8.48$6.52$4.55$2.59RES $10.27SUP $7.81$3.202026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACET Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACET Butterfly Map → + Track ACET →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ACET today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACET. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ACET today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACET)

Health Care Rank #732 of 1015 ⚔️ IXHL vs ACET Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACET vs. IXHL, LITS, RMTI, RNAZ)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Adicet Bio Inc. (ACET) ranks #732 by composite RQD confidence (32/100, grade E) and #793 by equity capitalization ($30.0M). Within this direct 5-issuer industry benchmark cohort, ACET leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. LITS currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ACET at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ACET ACTIVE
Adicet Bio Inc.
E 32/100 — — -35.0% -6.43% $30.0M Benchmark Subject
IXHL
Incannex Healthcare Inc.
D- 37/100 — — -35.0% -5.56% $29.9M /ixhl-vs-acet →
LITS
Lite Strategy Inc.
D- 43/100 — — -18.9% -13.60% $29.4M /lits-vs-acet →
RMTI
Rockwell Medical Inc.
E 23/100 — 16.9% -10.6% -2.26% $27.9M /rmti-vs-acet →
RNAZ
TransCode Therapeutics Inc.
D- 35/100 — — -35.0% 0.00% $27.6M /rnaz-vs-acet →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001720580 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Adicet Bio Inc. (ACET) reported GAAP revenue of $341.9M (-4.3% vs. FY2024 revenue of $357.3M , and -19.7% cumulative change since FY2023) , GAAP net income of -$116.8M, operating cash flow of -$95.2M, and free cash flow of -$97.0M (-3.7% YoY). On the balance sheet, ACET closed FY2025 with $192.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $341.9M -$116.8M -$95.2M -$97.0M $192.4M —
FY2024 (FY) 2024-12-31 $357.3M -$117.1M -$92.4M -$93.5M $220.2M —
FY2023 (FY) 2023-12-31 $425.7M -$142.7M -$93.7M -$93.7M — —

3. ACET Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACET stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Adicet Bio Inc. (NASDAQ: ACET) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.20 (-6.43% 1D, market cap $30.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ACET ranks #732 in composite RQD confidence.

How does ACET compare to IXHL and LITS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACET carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IXHL (Incannex Healthcare Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $29.9M) and LITS (Lite Strategy Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -18.9%, cap $29.4M). Among the 5-stock peer group, ACET leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ACET?

Per ACET's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001720580), Adicet Bio Inc. generated $341.9M in revenue (-4.3% YoY), -$116.8M in net income, and -$97.0M in free cash flow against $192.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ACET trading relative to its 50-day, 200-day, and 52-week technical levels?

ACET last traded at $3.20 (-6.43% on volume of 250,317 shares), positioning the stock -53.01% below its 50-day simple moving average ($6.81) and -58.01% below its 200-day simple moving average ($7.62). Across its 52-week range of $3.20 to $11.82, ACET sits at the 0.0% percentile with a 14-day RSI of 20.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.80 to $3.60).

Direct Sub-Reports: ACET RQD Cockpit ACET 12M Forecast ACET Earnings & Move ACET Dividends & DRIP ACET Insiders & 13F ACET Whale Options ACET Profit Sankey ACET News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

ACET — Adicet Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Adicet Bio Inc. (ACET) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.20 (-6.43% 1D, market capitalization $30.0M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Adicet Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — in each of the listed periods, indicating no reported revenue in the financial data provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Adicet Bio Inc. (ACET) reported $341.9M in annual revenue (up from $357.3M in FY2024, -4.3% YoY) and -$116.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($425.7M revenue, -$142.7M net income) through FY2025, ACET scaled operating cash flow to -$95.2M and free cash flow to -$97.0M, backed by $192.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.20 – $11.82 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ACET carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can ACET sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $341.9M and free cash flow of -$97.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ACET's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ACET Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Adicet Bio Inc. (ACET) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ACET Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACET Bull vs. Bear Conversation Board — What's Your Call at $3.20?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACET 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ACET:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $4.38 (+28.1%)
📌 Pinned Debate

Forensic balance sheet pillar scores 10 out of 20 with an Altman Z of 2.5 and a debt-to-equity of 0.5, the strongest signal in the RQD

Picked up a starter position in ACET in my $100K Virtual Cash book at $3.42. Forensic balance sheet pillar scores 10 out of 20 with an Altman Z of 2.5 and a debt-to-equity of 0.5, the strongest signal in the RQD rating.. Trading inside a $3.32–$12.32 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

EarningsSniper 🐂 BULL

Both sides have a point here — ACET's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $2.63 (-23.1%)
Spot @ $3.42

ROIC of -35%, FCF of -$97.0M in FY 2025, and zero reported revenue leave no demonstrated cash-generation engine.

Careful chasing ACET at $3.42. ROIC of -35%, FCF of -$97.0M in FY 2025, and zero reported revenue leave no demonstrated cash-generation engine.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $2.63 on multiple compression.

LIVE TAPE